Impact of PAF antagonist BN 52021 (Ginkolide B) on post-ischemic graft function in clinical lung transplantation
- 1 March 2001
- journal article
- clinical trial
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 20 (3) , 358-363
- https://doi.org/10.1016/s1053-2498(00)00226-6
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Experience with lung transplantationThe Annals of Thoracic Surgery, 1999
- Hypoxia-Induced Interleukin-6 and Interleukin-8 Production Is Mediated by Platelet-Activating Factor and Platelet-Derived Growth Factor in Primary Human Lung CellsAmerican Journal of Respiratory Cell and Molecular Biology, 1998
- Platelet-activating Factor Plays a Pivotal Role in the Induction of Experimental Lung InjuryAmerican Journal of Respiratory Cell and Molecular Biology, 1998
- A New Platelet-Activating Factor Antagonist (CV-6209) in Preservation of Heart and Lung for TransplantationCardiovascular Drugs and Therapy, 1997
- Studies on the mechanism of PAF-induced vasopermeability in rat lungsProstaglandins, Leukotrienes & Essential Fatty Acids, 1995
- Platelet activating factor antagonist enhances lung preservationJournal of Surgical Research, 1992
- Future horizons of lung preservation by application of a platelet-activating factor antagonist compared with current clinical standardsThe Journal of Thoracic and Cardiovascular Surgery, 1992
- Platelet Activating Factor (PAF)Drugs, 1991
- LONG-TERM LUNG PRESERVATION WITH THE PAF ANTAGONIST BN 52021Transplantation, 1991
- Regulation of Eicosanoid Generation in Activated MacrophagesInternational Archives of Allergy and Immunology, 1991